ReviewFrontiers in immunology2025
Pediatric inflammatory bowel disease and cancer.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Children with inflammatory bowel disease (IBD) have a higher risk of cancer due to prolonged exposure to chronic inflammation and immunosuppressive therapies. Methods: A comprehensive review of extant literature was performed. Findings: The cancer landscape in pediatric IBD is complex, with colorectal cancer, small intestine cancer, lymphoma, cholangiocarcinoma/hepatocellular carcinoma, and skin cancer being predominant concerns. The underlying pathogenic mechanisms involve genomic instability induced by chronic inflammation, carcinogenic effects of immunosuppressants, and environmental factors (e.g., high-fat diet and air pollution). Effective cancer surveillance is crucial in mitigating risk. Strategies include early endoscopic monitoring for high-risk populations, routine dermatological assessments, and clinical monitoring for tumor-related symptoms. Conclusion: This review synthesizes current evidence on the epidemiological characteristics, pathogenic mechanisms, and clinical management strategies for IBD-related malignancies in children. An in-depth characterization of the mechanisms by which pediatric IBD contributes to tumorigenesis is essential for developing surveillance protocols and advancing research to reduce tumor-associated morbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.